Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy

Pediatric Neurology

Volumn 41, Issue 2, 2009, Pages 119-123

  Thannhauser, Jennifer E ^a   Mah, Jean K ^a   Metz, Luanne M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVIEW; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PEER GROUP; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; INTERVIEWS AS TOPIC; KAPLAN-MEIERS ESTIMATE; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PEER GROUP; PEPTIDES; YOUNG ADULT;

EID: 67649599130     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2009.03.004     Document Type: Article

References (28)

1. Boiko A., Vorobeychik G., Paty D., Devonshire V., and Sadovnick D. University of British Columbia MS Clinic neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 59 (2002) 1006-1010
2. Kalb R.C., DiLorenzo T.A., et al. The impact of early-onset multiple sclerosis on cognitive and psychosocial indices. Int Journal MS Care 1 (1999) 1-6. http://www.mscare.com [Available at: http://www.mscare.com]
3. Rao S.M., Leo G.J., Ellington L., Nauertz T., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis. Neurology 41 (1991) 692-696
4. Banwell B.L. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep 4 (2004) 245-252
5. Sluder J.A.D., Newhouse P., and Fain D. Pediatric and adolescent multiple sclerosis. Adolesc Med 13 (2002) 461-485
6. Boyd J.R., and MacMillan L.J. Experiences of children and adolescents living with multiple sclerosis. J Neurosci Nurs 37 (2005) 334-342
7. MacAllister W.S., Boyd J.R., Holland N.J., Milazzo M.C., and Krupp L.B. International Pediatric MS Study Group. The psychosocial consequences of pediatric multiple sclerosis. Neurology 68 (2007) S66-S69
8. McCabe M.P., McKern S., and McDonald E. Coping and psychological adjustment among people with multiple sclerosis. J Psychosom Res 56 (2004) 355-361
9. Ghezzi A. Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurother 5 (2005) 403-411
10. Banwell B., Ghezzi A., Bar-Or A., Mikaeloff Y., and Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6 (2007) 887-902
11. Pohl D., Rostasy K., Gärtner J., and Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon β1a. Neurology 64 (2005) 888-890
12. Banwell B., Reder A.T., Krupp L., et al. Safety and tolerability of interferon β1b in pediatric multiple sclerosis. Neurology 66 (2006) 472-476
13. Ghezzi A., Amato M.P., Capobianco M., et al. Immunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 11 (2005) 420-424
14. Clerico M., Barbero P., Contessa G., Ferrero C., and Durelli L. Adherence to interferon-β treatment and results of therapy switching. J Neurol Sci 259 (2007) 104-108
15. Rio J., Porcel J., Téllez N., et al. Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11 (2005) 306-309
16. Portaccio E., Zipoli V., Siracusa G., Sorbi S., and Amato M.P. Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis. Eur Neurol 59 (2008) 131-135
17. Stata Statistical Software: Release 9 (2005), Stata Corp, College Station, TX
18. Strauss A., and Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. 2nd ed (1998), Sage, Newbury Park, CA 57-241
19. Thannhauser J. Data analysis. In: Psychosocial experiences in early-onset multiple sclerosis: grief-peer dynamic (2008), VDM Verlag, Saarbrücken, Germany 65-110
20. Pritchard M.T., Butow P.N., Stevens M.M., and Duley J.A. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. Am J Pediatr Hematol Oncol 28 (2006) 816-823
21. Smith B., and Wood B. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr Opin Pediatr 19 (2007) 553-558
22. Costello I., Wong I.C., and Nunn A.J. A literature review to identify interventions to improve the use of medicines in children. Child Care Health Dev 3 (2004) 647-665
23. Rapoff M.A. Management of adherence and chronic rheumatic disease in children and adolescents. Best Pract Res Clin Rheumatol 20 (2006) 301-314
24. Brooks-Gunn J. Why do adolescents have difficulties adhering to health regimes?. In: Krasnegor N.A., Epstein L., Johnson S.B., and Yaffe S.J. (Eds). Developmental aspects of health compliance behavior (1993), Lawrence Erlbaum, Hillsdale, NJ 125-152
25. Shaw R.J. Treatment adherence in adolescents: development and psychopathology. Clin Child Psychol Psychiatry 6 (2001) 137-150
26. Smith B.A., and Shuchman M. Problem of nonadherence in chronically ill adolescents: strategies for assessment and intervention. Curr Opin Pediatr 17 (2005) 613-618
27. Erikson E.H. Eight ages of man. In: Childhood and society (1985), W.W. Norton, New York 261-265
28. Erikson E.H. The life cycle: epigenesis of identity. In: Identity: Youth and crisis (1968), W.W. Norton, New York 122-135